Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- HTA Thresholds & Geopolitical HTAEpisode 43 — 02 July 2026Examining emerging market HTA thresholds, orphan drug RWE demands, digital therapeutics evidence gaps, geopolitical HTA challenges, and precision medicine HEOR shifts.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast4 min
- HTA Methodology Shifts & Pricing PressuresEpisode 42 — 30 June 2026Examining evolving HTA methodologies in emerging markets, pricing pressures in Canada, RWE adoption hurdles in Latin America, and gene therapy evidence strategies in Asia-Pacific.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- CHMP Approvals, Aligned Pathway, JCA Scale-upEpisode 41 — 29 June 2026EMA CHMP approves eight treatments including rare disease; MHRA-NICE issues first aligned guidance; EU JCA scales up to 50 assessments with capacity challenges.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast5 min
- JCA Reports & Regulatory DivergenceEpisode 40 — 28 June 2026JCA reports reveal HTA evolution, while ADC evidence gaps and regulatory divergence challenge commercial strategies.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast4 min
- RWE, Gene Therapy, IRA Evidence ChallengesEpisode 39 — 27 June 2026Examining evolving HTA evidence demands, gene therapy value hurdles, and IRA-driven HEOR shifts. Contrarian perspectives on RWE adoption and evidence generation priorities.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast7 min
- HTA Realities & RWE GapsEpisode 38 — 26 June 2026Examining FDA accelerated oncology approvals, EMA adaptive trial updates, NICE's new cell gene therapy framework, and emerging Asia-Pacific HTA collaboration.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast4 min
- Divergent PathwaysEpisode 37 — 25 June 2026Interim CDF recommendations for ADCs, NICE reversal on MRD endpoints, regulatory crises, JSC submissions, and EMA emergency trials.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast5 min
- Regulatory Divergence HEOR ImpactsEpisode 36 — 25 June 2026Examining regulatory divergence impacts on HEOR strategies and recent NICE reversals on MRD endpoints.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast7 min
- PRAC Valproate, JCA Scale-Up, EMA Emergency TrialsEpisode 35 — 22 June 2026Examining PRAC valproate conclusions, EU JCA capacity expansion, EMA emergency trial frameworks, oral semaglutide UK access, and tovorafenib JCA procedural timelines.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast4 min
- First JCA Report, Oral Wegovy, Camizestrant DivergenceEpisode 34 — 17 June 2026Episode 34 unpacks the publication of Europe's first completed JCA report for tovorafenib and what it signals for submissions in the pipeline, the MHRA approval of oral semaglutide and the distinct NICE appraisal challenge it creates, AstraZeneca's camizestrant caught between EU approval and US ODAC rejection, and the PRAC's conclusions on paternal valproate exposure. Marcus and Sara disagree on whether the JCA's handling of indirect comparisons is reassuring or a false comfort, and on whether the camizestrant EU approval is strategically premature.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast14 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.